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b Medical Oncology Division, Hospital Universitario La Princesa, Madrid, SpainThe pharmacological modulation of proteins and molecules related up-regulation of FASN in precursor lesionsmight represent an obligatory
to cancer is an important goal for translational science. Fatty acid
synthase (FASN) is a complex dimeric protein that converts acetyl-CoA
and malonyl-CoA into palmitic acid in a NADPH-dependent reaction in
mammalian cells (Maier et al., 2006). Many cancers present a strong
FASN expression and high enzymatic activity, and in recent years FASN
has emerged as a relevant anticancer target. So far, several compounds
have been reported to inhibit the enzymatic activity of FASN and to
have an effect on the growth of malignant cells. Some of these
compounds exhibit pharmacological limitations or induce weight
loss, preventing their development as systemic drugs. In this issue
of EBioMedicine, Ventura et al. report the characterization of the
anti-tumor activity of TVB-3166, a potent and orally available FASN
inhibitor that may provide a novel approach for cancer therapy
(Ventura et al., 2015). The authors observed that FASN inhibition
with TVB-3166 was able to induce apoptosis, to inhibit anchorage-
independent cell growth under lipid-rich conditions, and to inhibit
in vivo xenograft tumor growth in a dose-dependent manner without
affecting non-cancer cells.
FASN plays a critical role in a number of metabolic functions by
catalyzing the terminal steps in the synthesis of long-chain saturated
fatty acids. There is a strong FASNexpression andhigh enzymatic activity
in many cancers especially in carcinomas (Sebastiani et al., 2006), while
FASN is expressed at low levels in most normal tissues, except the liver,
adipose tissue, and lactating mammary gland (Sul and Wang, 1998),
suggesting that cancer cells are more dependent on de novo palmitate
synthesis catalyzed by FASN than normal cells (Menendez and Lupu,
2007). Palmitate and palmitate-derived lipids are essential components
in cancer cell proliferation and survival as they provide energy metabo-
lism and storage, membrane biosynthesis, and architecture and protein
localization and activity. The well-documented upregulation of FASN
in many human cancers as well as its association with poor clinical
outcome (Witkiewicz et al., 2008) both strengthen the hypothesis that
FASN is involved in the development, maintenance, and enhancement
of the malignant phenotype. Interestingly, increased FASN expression
has also been observed in some pre-neoplastic lesions and increases
with tumor progression, supporting the hypothesis that the earlyDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.020.
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through multiple mechanisms.
In the report by Ventura et al., the evidence for a role of FASN as a
therapeutic target comes from both in vitro and in vivo models of
human cancers. The authors found that pharmacological inhibition of
FASN using TVB-3166 causes an increase in apoptosis in breast and
prostate cancer cell lines. Interestingly, this response is not observed in
non-cancer cells. These ﬁndings are consistent with previous reports
that also used other FASN inhibitors (Brusselmans et al., 2003; Puig
et al., 2009). The authors describe here unreported mechanisms of action
including alteration on lipid raft architecture, palmitoylated protein local-
ization disruption and inhibition of signal transduction through the PI3K-
AKT-mTOR and ß-catenin pathways. The effect of TVB-3166 on lipid raft
architecture was examined using immuno-ﬂuorescent confocal micros-
copy to check palmitoylated protein localization. The data reveal that
FASN inhibition disrupts lipid raft distribution in themembranes, altering
the localization of raft-associated proteins such as N-Ras, inhibitsmultiple
signal transduction pathways including PI3K-AKT-mTPOR and B-catenin,
andmodulating the expressionof several genes inmetabolic, proliferation
and apoptosis pathways.
In addition to in vitro experiments, Ventura et al. also present impor-
tant results using in vivomodels. The authors show that FASN inhibition
has anti-tumor activities in biologically diverse preclinical tumor models,
including those expressing mutant K-Ras, ErbB2, c-Met, and PTEN. These
results are globally in agreement with previous publication in which
treatments with siRNA or chemical inhibitors of FASN have been shown
to decrease tumor size in animal models of various types of cancers
(De Schrijver et al., 2003; Puig et al, 2011). Finally, the authors performed
both genetic and expression analyses and found that FASN inhibition
modulates genes involved in lipid synthesis, signal transduction, cell
cycle and apoptosis pathways. It may be very relevant for future develop-
ment that those pathways were not affected in non-cancer cells.
In conclusion, the results from this report show the potency, selectiv-
ity, reversible mechanism of action and in vivo availability of the FASN
inhibitor TVB-3166, differentiating it from earlier FASN inhibitors such
as C75 or cerulenin. The authors found that TVB-3166 modulates lipid
synthesis, signal transduction, cell cycle and apoptosis pathways in both
in vitro cell culture and in vivo tumor xenograft models. These results
represent an important step in discovering the multiple mechanisms of
action of FASN and pave the way for the identiﬁcation of biomarkers
with potential utility as predictive factors.C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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